Printer Friendly

SCIOS NOVA INC. REACQUIRES RIGHTS TO RECOMBINANT HUMAN LUNG SURFACTANT

SCIOS NOVA INC. REACQUIRES RIGHTS TO RECOMBINANT HUMAN LUNG SURFACTANT
 MOUNTAIN VIEW, Calif., Nov. 2 /PRNewswire/ -- Scios Nova, Inc. (NASDAQ-NMS: SCIO) today announced that it has reacquired the rights to the recombinant human lung surfactant (hLS) previously licensed to Genentech, Inc. (NYSE: GNE). Lung surfactant is a treatment for infant respiratory distress syndrome (RDS), a principal cause of death in premature infants. Lung surfactants may also be effective in the treatment of adult RDS, a condition associated with high mortality for which there are no existing treatments.
 In 1989, Scios and Genentech signed an agreement for the collaborative development of therapeutic uses of recombinant hLS. Under the terms of the new agreement, all rights to the recombinant hLS technology were returned to Scios Nova, including worldwide marketing and manufacturing rights. In return, Scios Nova issued common stock to Genentech. Upon marketing approval, Scios Nova will issue additional common stock and will pay a royalty on sales of recombinant hLS.
 Surfactant is a mixture of lung-specific proteins and fats produced in late pregnancy. Surfactant coats the surfaces of the lungs and enables a person's lungs to remain expanded and fully functional. Premature babies, born with insufficient surfactant, risk lung collapse. In adults, a decrease in surfactant caused by a variety of conditions may also lead to collapse of the lungs or suboptimal lung performance.
 "The life-saving benefit of lung surfactants in infants has been well established in clinical studies," said Richard L. Casey, Scios Nova president and chief executive officer. "We are pleased to have the opportunity to spearhead the further development of recombinant hLS to treat RDS in infants and adults. We intend to seek a new partner to work with us to develop this important technology."
 Scios Nova Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios Nova focuses its efforts in four areas: cardiovascular disease, inflammation, metabolic disorders and tissue repair. The company's drug discovery technology encompasses both biotechnology techniques and small molecule design to develop new biopharmaceutical products. Scios Nova develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical companies.
 -0- 11/02/92
 /CONTACT: Kira Bacon of Scios Nova Inc., 415-940-6629, or Lynne Brum of Feinstein Partners, 617-577-8110, for Scios Nova/ CO: Scios Nova Inc.; Genentech ST: California IN: MTC SU: CON


CH -- NE004 -- 1530 11/02/92 10:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 2, 1992
Words:398
Previous Article:COLUMBIA BANKING SYSTEM INC. REPORTS INCREASED THIRD-QUARTER EARNINGS
Next Article:ENSERCH REPORTS THIRD-QUARTER RESULTS
Topics:


Related Articles
SCIOS NOVA ANNOUNCES NEW VICE PRESIDENT OF PRODUCT DEVELOPMENT
U.S. PATENT AND TRADEMARK OFFICE RULES IN FAVOR OF SCIOS NOVA'S FIBROBLAST GROWTH FACTOR
SCIOS NOVA'S PHASE I/II CLINICAL STUDY OF NATRECOR(R) BNP SHOWS STATISTICALLY SIGNIFICANT IMPROVEMENT IN CARDIAC FUNCTION
SCIOS NOVA FILES REGISTRATION STATEMENT FOR SHARES ISSUED TO GENENTECH
SCIOS NOVA RECEIVES U.S. PATENT FORTRANSGENIC MICE DISPLAYING AMYLOID DEPOSITS ASSOCIATED WITH ALZHEIMER'S DISEASE
SCIOS INC. ANNOUNCES NAME CHANGE
SCIOS RECEIVES U.S. PATENT FOR THE RECOMBINANT PRODUCTION OF FIBLAST(R) TRAFERMIN (bFGF)
SCIOS AND GENENTECH REAFFIRM AURICULIN AGREEMENT AND ADJUST TIMELINE FOR MILESTONE PAYMENT
EUROPEAN PATENT OFFICE RULES IN FAVOR OF SCIOS FOR FIBLAST(R) TRAFERMIN (bFGF)
Genetics Institute and Affymetrix Sign New Agreement and Extend GeneChip(R) Technology Access to DiscoverEase(R) Participants

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters